THE EXPERIMENTAL DEVELOPMENT OF BIOREDUCTIVE DRUGS AND THEIR ROLE IN CANCER-THERAPY

被引：152

作者：

WORKMAN, P

STRATFORD, IJ

机构：

[1] MRC,RADIOBIOL UNIT,DIDCOT OX11 0RD,OXON,ENGLAND

[2] UNIV GLASGOW,CANC RES CAMPAIGN,BEATSON LABS,CRC DEPT MED ONCOL,GLASGOW G6 1BD,SCOTLAND

来源：

CANCER AND METASTASIS REVIEWS | 1993年 / 12卷 / 02期

基金：

英国医学研究理事会;

关键词：

BIOREDUCTION; HYPOXIA; REDUCTASES; THERAPY;

D O I：

10.1007/BF00689802

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bioreductive drugs undergo metabolic reduction to generate cytotoxic metabolites. This process is facilitated by bioreductive enzymes and the lower oxygen conditions present in solid tumours compared to normal tissues. Because of this specificity, bioreductive drugs have enormous potential to contribute to modern cancer therapy. Examples undergoing clinical trials include N-oxides such as tirapazamine, aziridinylnitroimidazoles RSU 1069/RBU 6145 and quinones such as indoloquinone EO9. Other novel structures are also under study. Here we review the experimental development of bioreductive drugs and their role in cancer therapy.

引用

页码：73 / 82

页数：10

共 85 条

[1] BIOREDUCTIVE DRUGS AS POSTIRRADIATION SENSITIZERS - COMPARISON OF DUAL FUNCTION AGENTS WITH SR-4233 AND THE MITOMYCIN-C ANALOG-EO9 [J].